To its everlasting credit, the participation and commitment of the AFIP to this venture is even more substantial and encompassing than in previous series. It now extends to virtually all scientific, technical, and financial aspects of the production.
The task confronting the organizations and individuals involved in the third series is even more daunting than in the preceding efforts because of the ever-increasing complexity of the matter at hand. It is hoped that this combined effort-of which, needless to say, that represented by the authors is first and foremost-will result in a series worthy of its two illustrious predecessors and will be a suitable introduction to the tumor pathology of the twenty-first century.
Juan Rosai, M.D.
Leslie H. Sobin, M.D.
